About polatuzum ab vedotin
CD79b-directed antibody-drug conjugate
Used for
- With other medicines, treats adults with diffuse large B-cell lymphoma.
- Used for lymphoma that has returned or not responded to previous treatment.
Usual adult dose
Usually 1.8 mg/kg by intravenous infusion every 21 days, with other medicines; dosing and duration depend on the treatment plan.
Common side effects
- Nerve damage causing numbness, tingling, or weakness
- Low blood cell counts and infections
- Diarrhea, nausea, or vomiting
- Infusion reactions and fatigue
Important warnings
- Can cause serious infections and low blood cell counts.
- Nerve damage may require treatment interruption or dose changes.
- Serious liver injury and infusion reactions can occur.
- Treatment requires monitoring by a cancer specialist.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least two months after the last dose.
Interactions
- Medicines affecting CYP3A enzymes may alter treatment exposure; examples include strong inhibitors or inducers.
- Some medicines that affect drug transport proteins may change exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.